Similarly, in the recent study by Jarosz-Griffiths et al., a steady decrease of IL-1β levels was observed in serum from a cohort (n=8) of F508del-homozygous CF patients during three months of the combination ivacaftor/tezacaftor therapy. This evidence concerns the gene IL1B and cystic fibrosis.